Ribociclib

Introduction Overview

Generic Name

ribociclib

Brand Name

Kisqali

Dosage Form

oral tablet

Drug Class

CDK 4/6 inhibitors

Pharmacokinetics

Absorption: Ribociclib, the active component of Kisqali, demonstrates rapid and extensive oral absorption with peak plasma concentrations achieved approximately 1 to 4 hours post-administration. Bioavailability is augmented by its solubility and permeability characteristics, and Kisqali can be administered with or without food without significant impact on its pharmacokinetic profile. The drug's oral absorption is efficient, allowing for once-daily dosing to maintain therapeutic plasma concentrations.

Distribution: Ribociclib exhibits a large volume of distribution indicative of extensive tissue penetration. It binds extensively to plasma proteins, primarily albumin, with approximately 70% protein binding, facilitating sustained systemic exposure. Its distribution favors key tissues including tumor sites, though the penetration across the blood-brain barrier is limited. Distribution is influenced by transporter proteins such as P-glycoprotein, which can affect tissue and cellular uptake.

Metabolism: Ribociclib undergoes extensive hepatic metabolism primarily via cytochrome P450 isoenzyme CYP3A4, producing several metabolites, some of which have pharmacological activity but are less potent than the parent compound. The metabolic pathway involves oxidative biotransformation yielding hydroxylated and N-demethylated metabolites. Drug interactions involving CYP3A4 inhibitors or inducers can significantly alter ribociclib plasma concentrations, necessitating dose adjustments. Genetic polymorphisms affecting CYP3A4 may also influence metabolism and patient response.

Elimination: The elimination of ribociclib occurs mainly via fecal excretion, with approximately 69% of the administered dose recovered in feces and about 23% eliminated renally. Its elimination half-life ranges from 32 to 55 hours, supporting once-daily dosing with intermittent off-treatment periods to manage toxicity. Renal or hepatic impairment can affect drug clearance, requiring careful monitoring. The pharmacokinetic profile supports a 21-days-on, 7-days-off cycle for optimal efficacy and safety in clinical use.

Dosage Forms

Available Dosage Forms: Kisqali is formulated as oral tablets, available exclusively in a 200 mg strength per tablet. The tablets contain active ribociclib along with inactive ingredients such as colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and a film coating composed of iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum. These tablets are film-coated and intended for oral administration swallowed whole.

Dosages for Adults and Adolescents: The approved dosing regimen for Kisqali varies based on the type and stage of breast cancer treatment. For early-stage breast cancer with a high risk of recurrence, the recommended dose is 400 mg daily (two 200 mg tablets) orally for 21 consecutive days followed by 7 days off treatment to complete a 28-day cycle. In advanced or metastatic breast cancer, the starting dose is higher at 600 mg daily (three 200 mg tablets) for 21 consecutive days, followed by 7 days off, per 28-day treatment cycle. Dose modifications including interruptions and reductions are based on individual tolerability and toxicity. Currently, Kisqali is indicated for adults, with limited pediatric data.

Specific Patient Populations: Dose adjustments may be necessary for patients with hepatic or renal impairment due to altered metabolism and elimination pathways. Ribociclib is contraindicated or used with caution in patients with pre-existing QT interval prolongation or cardiomyopathy. Treatment in patients with fertility concerns requires counseling due to potential effects on male fertility. For pregnant or breastfeeding females, Kisqali is contraindicated given known teratogenic risks and absence of data on excretion in human milk. Patients should be monitored rigorously during therapy, especially older adults or those with comorbid conditions.

Mechanism Of Action

Ribociclib, the active agent in Kisqali, functions as a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes crucial for cell cycle progression. These kinases regulate the transition from the G1 phase to the S phase by phosphorylating the retinoblastoma protein (Rb), thereby releasing E2F transcription factors necessary for DNA synthesis. By inhibiting CDK4/6, ribociclib prevents Rb phosphorylation, leading to G1 cell cycle arrest, effectively halting proliferation of cancer cells particularly in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer cells.

At the cellular signaling level, ribociclib's inhibition of CDK4/6 disrupts downstream pathways that promote cell survival and replication, enhancing the efficacy of concurrent hormone therapies such as aromatase inhibitors or fulvestrant. This synergistic effect improves disease control in cancers driven by estrogen signaling. Unlike traditional chemotherapy, Kisqali targets specific molecular drivers of cell cycle dysregulation, offering a targeted approach with a distinct side effect profile.

Preclinical and clinical studies demonstrate that ribociclib effectively reduces tumor cell proliferation markers and induces sustained cell cycle arrest. Comparative mechanistically to other CDK4/6 inhibitors like palbociclib and abemaciclib, ribociclib has a similar mode but differs in pharmacokinetic properties and toxicity profiles, influencing clinical choice. The inhibition of CDK4/6 also modulates the tumor microenvironment and may overcome resistance mechanisms associated with hormonal therapies.

Overall, Kisqali's mechanism directly targets key regulators of cancer cell cycle machinery, translating into improved progression-free and overall survival benefits in treated patients, as demonstrated in pivotal clinical trials. Ongoing research is exploring combination regimens and resistance pathways to optimize utilization of CDK4/6 inhibitors.

Pharmacological Actions

Selective inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), impeding cell cycle progression.
Induction of G1 phase cell cycle arrest in HR+/HER2- breast cancer cells.
Potentiation of endocrine therapy through synergistic effects with aromatase inhibitors and fulvestrant.
Targeted anti-proliferative effect sparing non-dividing normal cells, resulting in a distinct toxicity profile from chemotherapy.
Modulation of tumor microenvironment contributing to enhanced antitumor activity.
Reduction of phosphorylation of retinoblastoma protein (Rb), controlling E2F transcription factor activity.
Impact on downstream signaling pathways regulating DNA synthesis and cell survival.
Potential delay or overcoming of resistance to hormone therapy by dual pathway targeting.
Exerts cytostatic rather than cytotoxic effects, limiting tumor growth progression.
Supports improved overall survival and progression-free survival in HR+/HER2- breast cancer patients.
Facilitates combination use with hormone therapies enhancing treatment efficacy.
Displays oral bioavailability facilitating convenient dosing schedules.
Selective kinase profile minimizing off-target toxicities.
Is metabolized primarily via CYP3A4, influencing pharmacological action and drug interactions.

Therapeutic Or Clinical Uses

Treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Use in combination with aromatase inhibitors for stage II and III early breast cancer patients at high risk of recurrence.
Management of advanced or metastatic breast cancer in combination with aromatase inhibitors as initial endocrine therapy.
Treatment of advanced or metastatic breast cancer in combination with fulvestrant for first endocrine-based therapy or post-progression on endocrine therapy.
Extends progression-free survival when added to hormone therapy in appropriate breast cancer subtypes.
Helps to delay disease progression in metastatic settings.
Serves as a targeted therapy alternative to chemotherapy with fewer systemic toxicities.
Used in pre- and postmenopausal women with HR+/HER2- breast cancer.
Indicated for patients with intolerance or resistance to other endocrine therapies.
Part of combination treatment regimens facilitating improved overall survival in metastatic breast cancer.
Provides option for maintenance therapy following initial response to hormonal agents.
Appropriate for patients requiring oral systemic therapy with manageable side-effect profile.
Utilized in clinical settings adhering to 21 days on treatment / 7 days off cycles.
Can be co-packaged with letrozole (Femara) for convenient administration.
Offers treatment option that modulates cell cycle dysregulation, a key oncogenic driver.

Side Or Adverse Effects

Neutropenia manifesting as decreased white blood cell counts leading to increased infection risk.
Anemia and thrombocytopenia indicated by reduced red blood cell and platelet counts respectively.
Elevations in liver enzymes (transaminases) reflecting potential hepatotoxicity.
Infections including upper respiratory tract infections and other systemic infections due to immunosuppression.
Gastrointestinal disturbances such as nausea, diarrhea, vomiting, and constipation.
Fatigue and tiredness impacting patient quality of life.
Headache as a commonly reported neurological symptom.
Hair thinning or alopecia observed in a subset of patients.
Serious lung problems including severe or life-threatening pneumonitis or interstitial lung disease.
QT interval prolongation on electrocardiogram with potential for fatal arrhythmias.
Severe skin reactions including rash, blistering, and Stevens-Johnson syndrome-like features.
Hepatic dysfunction manifesting as jaundice, tea-colored urine, abdominal pain, and altered liver function tests.
Risk of febrile neutropenia requiring dose interruptions or reductions.
Gastrointestinal discomforts such as abdominal pain or reflux.
Electrolyte imbalances secondary to vomiting or diarrhea.

Precautions

Regular monitoring of complete blood counts to detect neutropenia and manage infection risk.
Frequent liver function tests to identify early signs of hepatotoxicity.
Cardiac monitoring including baseline and periodic ECGs to evaluate QT interval changes.
Avoid concomitant use with strong CYP3A inhibitors or inducers to prevent altered plasma levels of ribociclib.
Use with caution in patients with pre-existing cardiac disease or arrhythmias.
Counsel patients on signs and symptoms of infection, lung inflammation, or liver injury.
Advise patients to avoid grapefruit products due to CYP3A4 interactions.
Evaluate electrolyte levels periodically, correcting abnormalities to mitigate QT prolongation.
Monitor for and manage severe skin reactions promptly.
Use effective contraception in women of childbearing potential and counsel on teratogenic risk.
Avoid breastfeeding during treatment and for at least three weeks after last dose.
Adjust dosing or interrupt therapy based on toxicity severity and tolerability.
Assess renal and hepatic function before and during therapy to guide dosing adjustments.
Inform male patients about potential fertility impairment.
Educate patients to take Kisqali at the same time daily, preferably in the morning.

Warnings

Potential for severe or fatal lung inflammation requiring immediate medical attention.
Risk of life-threatening cardiac arrhythmias due to QT interval prolongation.
Severe hepatotoxicity including fatal liver failure reported; requires prompt discontinuation if occurs.
Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Significant neutropenia increasing risk for opportunistic and severe infections.
May cause embryofetal toxicity; contraindicated in pregnancy.
Avoid use with drugs that prolong QT interval or strong CYP3A inhibitors.
Potential for dose-dependent toxicities necessitating careful dose management.
Not recommended for use in breastfeeding mothers due to unknown effects on infants.
May result in electrolyte abnormalities exacerbating cardiac risks.
Risk of tumor lysis syndrome in patients with high tumor burden.
Use cautiously in patients with uncontrolled hypertension or recent myocardial infarction.
Patients should be monitored closely during the first cycles for adverse effects.
Avoid abrupt discontinuation without medical advice due to risk of disease progression.
May cause dizziness or fainting related to cardiac side effects.

Contraindication

Known hypersensitivity to ribociclib or any of the excipients.
Pregnancy due to potential for fetal harm and teratogenicity.
Severe hepatic impairment without ability to monitor and adjust dosing accordingly.
Concurrent use with strong CYP3A4 inhibitors that cannot be avoided.
Patients with congenital long QT syndrome.
Baseline QT interval prolongation above recommended thresholds.
Severe uncontrolled cardiac conditions including heart failure and arrhythmias.
Breastfeeding during treatment and for at least 3 weeks post-treatment.
Concurrent use with drugs known to prolong QT interval and cause torsades de pointes.
Presence of significant electrolyte imbalances uncorrectable prior to therapy.
Severe neutropenia or baseline hematologic abnormalities precluding safe treatment initiation.
Patients unable to swallow oral tablets whole due to formulation limitations.
Use in pediatric patients has not been established and is thus contraindicated.
Use in patients with active infections contraindicated until resolved.
Hypersensitivity to other CDK4/6 inhibitors may warrant caution.

Drug Interactions

Strong CYP3A inhibitors such as clarithromycin, ketoconazole, ritonavir increasing ribociclib plasma levels and toxicity risk.
CYP3A inducers including rifampicin, phenytoin, St. John's Wort reducing ribociclib effectiveness by lowering concentrations.
Concomitant use of CYP3A substrates like midazolam, simvastatin may require dose adjustments due to altered metabolism.
Drugs that prolong QT interval including haloperidol, amiodarone, sotalol, macrolide and fluoroquinolone antibiotics raising risk of cardiac arrhythmias.
Caution with calcium channel blockers (diltiazem, verapamil) which may increase ribociclib plasma levels.
Concurrent administration with hormone therapies such as aromatase inhibitors (letrozole, anastrozole, exemestane) and fulvestrant is standard but requires monitoring.
Avoid grapefruit and grapefruit juice which inhibit CYP3A and elevate ribociclib exposure.
Glucocorticoids may induce CYP3A and reduce ribociclib efficacy.
Potential interaction with warfarin and other anticoagulants impacting bleeding risk due to hematologic effects.
Combining with other myelosuppressive agents increases risk of cytopenias.
Interaction with herbal supplements like goldenseal that inhibit CYP3A4 leading to increased drug toxicity.
Concomitant use with drugs affecting renal function may necessitate monitoring for altered ribociclib clearance.
Dose adjustments recommended in presence of interacting drugs to mitigate adverse events.
Careful medication reconciliation required to prevent fatal arrhythmias resulting from additive QT prolongation.
Monitoring for altered drug plasma concentrations during combination therapy is essential.

Preparations Of The Drug

Kisqali is prepared as film-coated 200 mg oral tablets containing active ribociclib succinate.
Inactive ingredients include colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose.
The tablet’s film coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum.
Available as a single strength tablet formulation facilitating precise dosing and titration.
Kisqali is also available as a co-packaged combination with the aromatase inhibitor letrozole branded as Kisqali Femara Co-Pack.
Tablets are supplied in blister packs to protect from moisture and physical damage.
Storage recommendations include refrigeration at 2°C to 8°C prior to dispensing, then room temperature storage at 20°C to 25°C up to 2 months after dispensing.
Manufactured by Novartis Pharmaceuticals Corporation under stringent quality control standards.
Tablets are designed to be swallowed whole without crushing or splitting to maintain pharmacokinetic integrity.
Preparation for administration requires patient education on adherence and proper tablet ingestion to ensure therapeutic efficacy.
Each batch undergoes rigorous testing for potency, purity, and stability before market release.
Packaging includes detailed prescribing information and patient counseling guides.
Formulation optimized for oral bioavailability and patient compliance.
Contains allergen excipients like soya lecithin requiring patient awareness.
Supplied with tamper-evident packaging to ensure medication safety.